Summary:
With outstanding know-how and expertise in PCR technology, a Korean biotech engineering SME has been developing and manufacturing ultra-fast molecular diagnosis platforms and in-vitro diagnostic kits for several years. The company is seeking collaboration with partners in Europe who can distribute the real-time PCR technology based easy-to-use COVID-19 diagnosis kit that dramatically reduces the testing time to 45 minutes.
Description:
Due to its high contagiousness and severeness, rapid detection of the virus should be performed as quickly as possible for setting up timely quarantine measure as well as proper medication and treatment.
A Korean company founded in 2010 is a biotech engineering company in South Korea specializes in molecular testing solutions to target multiplex on-site testing needs. The company also develops and manufactures state-of-the-art PCR platforms as well as related reagents and biochip products which are designed to enhance the health of human societies and ultimately improve the quality of human life.
Ongoing research and development efforts of the company led them to develop novel COVID19 diagnosis system which based on Ultra-fast real-time PCR system* and biochip.
Starting with this COVID19 diagnosis system (detection kit), the company wish to expand their market to Europe and later on to introduce their many other molecular testing solutions.
Real-time PCR is one of the most well-known methods with good sensitivity and high accuracy for disease diagnostics. However, this technology used to have some disadvantages such as long turn-around-time or complicated workflow. The Korean company proudly introduced novel coronavirus (SARS-CoV-2) detection kit which is based on biochip sample format and provides relatively short turn around-time with simple workflow while it offers key benefits of real-time PCR tests. The standard turn-around-time is 45 minutes using the company’s real-time PCR platform.
**Brief information of the configuration of Test chip:
Primers and probes for detection of N gene of SARS-CoV-2 are labeled in well number 2, 4, 6 and 8 while primers and probes for detection of RdRP gene of SARS-CoV-2 are labeled in well number 3, 5, 7 and 9. Well number 1 is for running no template control and well number 10 is for running positive control. With this configuration, 4 samples can be tested per a run.
The company is currently seeking global business partners in order to secure distribution channels in Europe, especially in the field of molecular diagnostics. Considering partnership types could be Commercial agency agreement or distribution services agreement.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The potential partner is expected to be able to directly distribute the products in local based on active marketing activities by its own. Specialized in molecular diagnostic would be the best, but any company capable of generating sales would be all welcomed as well.
Stage of Development:
Already on the market
IPR Status:
Patents granted,Trade Marks,Copyright
External code:
BOKR20200719001
